It’s Not a Buy? Why Valeant’s Stock Could Have 25% Upside

Yup! Things seem to be looking up for Valeant Pharmaceuticals International (VRX). The drug maker reported third quarter per-share profit that blew past expectations, albeit lowered expectations. Moody’s raised its outlook on the company’s debt to stable. And even bears admit that Valeant has made headway repairing its overly-leveraged balance sheet, launching new drugs and […]